دورية أكاديمية

Effects of MLC601 on Early Vascular Events in Patients After Stroke ; The CHIMES Study

التفاصيل البيبلوغرافية
العنوان: Effects of MLC601 on Early Vascular Events in Patients After Stroke ; The CHIMES Study
المؤلفون: Chen, Christopher L.H., Venketasubramanian, Narayanaswamy, Lee, Chun Fan, Wong, K.S. Lawrence, Bousser, Marie-Germaine, Navarro, Jose C., Gan, Herminigildo H., Lao, Annabelle Y., Baroque, Alejandro C., Lokin, Johnny, Hiyadan, John Harold B., Sarfati, Ma. Socorro, Fangonillo, Randolph John, Ambasing, Neil, Chua, Carlos L., San Jose, Ma. Cristina, Advincula, Joel M., Berame, Eli John, Canete, Maria Teresa, Young, Sherry H.Y., Mamauag, Marlie Jane, Tay, San San, Pande, Shrikant, Thirugnanam, Umapathi, Singh, Rajinder, Chang, Hui Meng, De Silva, Deidre Anne, Chan, Bernard P.L., Sharma, Vijay, Luen, Teoh Hock, Poungvarin, Niphon, Muengtaweepongsa, Sombat, Towanabut, Somchai, Suwanwela, Nijasri C., Chotickanuchit, Songkram, Chankrachang, Siwaporn, Nitinun, Samart, de Silva, H. Asita, Ranawake, Udaya, Wijekoon, Nirmala, Eow, Gaik Bee
المصدر: Stroke ; volume 44, issue 12, page 3580-3583 ; ISSN 0039-2499 1524-4628
بيانات النشر: Ovid Technologies (Wolters Kluwer Health)
سنة النشر: 2013
الوصف: Background and Purpose— Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. Methods— Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. Results— The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=−2.7%; 95% confidence interval, −5.1% to −0.4%; P =0.025) without an increase in nonvascular deaths. Kaplan–Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P =0.024; hazard ratio, 0.51; 95% confidence interval, 0.28–0.93). Conclusions— Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study. Clinical Trial Registration— URL: http://www.clinicaltrials.govTest . Unique identifier: NCT00554723.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1161/strokeaha.113.003226
DOI: 10.1161/STROKEAHA.113.003226
الإتاحة: https://doi.org/10.1161/strokeaha.113.003226Test
رقم الانضمام: edsbas.F8A372B1
قاعدة البيانات: BASE